HeartBeam (NASDAQ: BEAT) announced a strategic reorganization designed to accelerate execution, expand global market reach, and improve capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams to streamline decision-making, improve accountability, and reduce costs. Former CEO Robert Eno will transition into a consulting role.
The company’s strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The company holds over 20 issued patents related to technology enablement.
This reorganization comes as HeartBeam seeks to capitalize on its FDA clearance for the 12-lead ECG synthesis software, which received clearance in December 2025. The platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
For more details, view the full press release at https://ibn.fm/CTxXi. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025.
